Amanta Healthcare Allocates Rs 3,030 Crore from IPO Proceeds for Expansion

Amanta Healthcare Limited , a prominent pharmaceutical company, has reported progress in utilizing its Initial Public Offering (IPO) proceeds for the quarter ended September 30, 2025. The company has allocated funds towards its expansion plans, focusing on enhancing manufacturing capabilities at its Gujarat facility.

Key Highlights of Fund Utilization

Total Utilization: Amanta Healthcare has utilized Rs 3,030.02 lakhs from its IPO proceeds during the quarter.
Primary Focus: The funds were primarily directed towards capital expenditure, including manufacturing equipment and civil construction work.
Remaining Funds: The company still has Rs 9,569.98 lakhs available for further planned expansions.

Detailed Breakdown of Fund Allocation

Particulars	Amount (Rs in lakhs)
Total IPO Proceeds	12,600.00
Funds Utilized	3,030.02
Remaining Funds	9,569.98

Expansion Plans

SteriPort Manufacturing Line:
- Planned commencement: January 2026
- Location: Hariyala, Kheda, Gujarat
SVP (Small Volume Parenterals) Manufacturing Line:
- Planned commencement: January 2027
- Location: Hariyala, Kheda, Gujarat

Financial Performance

Amanta Healthcare's recent financial results for the quarter ended September 30, 2025, show:

Particulars	Q2 FY2026 (Rs in lakhs)
Total Income from Operations	7,095.80
Net Profit Before Tax	227.78
Net Profit After Tax	120.76

Management Commentary

Bhavesh Patel, Chairman & Managing Director of Amanta Healthcare, stated, "Our strategic utilization of IPO proceeds is aligned with our growth objectives. The investments in new manufacturing lines for SteriPort and SVP will significantly enhance our production capabilities and market position."

Future Outlook

The company's focus on expanding its manufacturing capabilities, particularly in SteriPort and SVP lines, indicates its commitment to growth and market expansion. The utilization of IPO funds and the planned commencement of new production lines in 2026 and 2027 suggest a roadmap for Amanta Healthcare's future development.

Investors and market analysts will likely monitor the progress of these expansion projects and their potential impact on the company's future financial performance and market position in the pharmaceutical sector.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+1.02%	-2.73%	-5.50%	-15.43%	-15.43%	-15.43%

Amanta Healthcare Limited (ISIN: INE084K01015) has reported a deviation in fund utilization for its Initial Public Offering (IPO) proceeds and released its financial results for the quarter ended September 30, 2025. The company, which raised Rs 126 crore through its IPO, has made adjustments to its fund allocation due to GST payment modifications.

Fund Utilization Deviation

The company disclosed that the deviation occurred due to changes in GST payments over the costs mentioned in the IPO Offer Document. This resulted in adjustments to issue expenses and a corresponding reduction in general corporate purpose expenses. The revised fund allocation is as follows:

Purpose	Original Allocation (Rs. in lakhs)	Revised Allocation (Rs. in lakhs)	Amount Utilized (Rs. in lakhs)	Amount Unutilized (Rs. in lakhs)
SteriPort manufacturing line at Hariyala, Kheda, Gujarat	7,000.00	7,000.00	764.81	6,235.19
SVP manufacturing line at Hariyala, Kheda, Gujarat	3,013.11	3,013.11	-	3,013.11
General corporate purposes	660.46	302.08	-	302.08
Issue Expenses	1,926.43	2,284.81	2,265.21	19.60
Total	12,600.00	12,600.00	3,030.02	9,569.98

The Audit Committee reviewed the statement and provided no comments on the deviation.

Q2 FY2026 Financial Highlights

Amanta Healthcare also released its unaudited financial results for the quarter and six months ended September 30, 2025:

Revenue from operations for Q2 FY2026 stood at Rs. 7,088.73 lakhs, compared to Rs. 6,673.12 lakhs in Q2 FY2025.
Profit before tax for Q2 FY2026 was Rs. 227.78 lakhs, down from Rs. 316.66 lakhs in the same quarter last year.
Net profit for Q2 FY2026 decreased to Rs. 120.75 lakhs from Rs. 225.70 lakhs in Q2 FY2025.

Half-Year Performance

For the six months ended September 30, 2025:

Revenue from operations reached Rs. 13,619.44 lakhs, up from Rs. 13,483.07 lakhs in the corresponding period of the previous year.
Profit before tax was Rs. 720.43 lakhs, compared to Rs. 266.24 lakhs in the same period last year.
Net profit increased to Rs. 471.47 lakhs from Rs. 189.50 lakhs in the previous year's corresponding period.

Balance Sheet Highlights

As of September 30, 2025:

Total assets stood at Rs. 48,831.55 lakhs, up from Rs. 38,175.85 lakhs as of March 31, 2025.
Total equity increased to Rs. 21,068.01 lakhs from Rs. 9,638.83 lakhs at the end of the previous fiscal year.
Cash and cash equivalents significantly improved to Rs. 9,196.41 lakhs from Rs. 22.06 lakhs as of March 31, 2025.

The company's financial position shows growth in assets and equity, with a substantial improvement in cash reserves. However, the quarterly profit has seen a decline compared to the same period last year. The fund utilization deviation reflects the company's adaptation to GST-related changes, with a focus on optimizing its manufacturing capabilities and managing issue expenses efficiently.

Amanta Healthcare continues to progress with its expansion plans, particularly in setting up new manufacturing lines for SteriPort and SVP products at its Hariyala facility in Kheda, Gujarat. The company's strategic allocation of IPO funds demonstrates its commitment to enhancing production capabilities while managing financial resources prudently.